Tyrphostin A1

CAS No. 2826-26-8

Tyrphostin A1 ( Tyrphostin 1;AG9 )

Catalog No. M20945 CAS No. 2826-26-8

Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 27 Get Quote
10MG 42 Get Quote
25MG 80 Get Quote
50MG 113 Get Quote
100MG 147 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Tyrphostin A1
  • Note
    Research use only not for human use.
  • Brief Description
    Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
  • Description
    Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .
  • Synonyms
    Tyrphostin 1;AG9
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2826-26-8
  • Formula Weight
    184.19
  • Molecular Formula
    C11H8N2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (542.92 mM)
  • SMILES
    COc1ccc(C=C(C#N)C#N)cc1
  • Chemical Name
    2-[(4-Methoxyphenyl)methylidene]propanedinitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Du C Bright J J Sriram S . Inhibition of CD40 signaling pathway by tyrphostin A1 reduces secretion of IL-12 in macrophage Th1 cell development and experimental allergic encephalomyelitis in SJL/J mice[J]. Journal of Neuroimmunology 2001 114(1-2):69-79.
molnova catalog
related products
  • (1R,2R)-Trans-N-Boc-...

    Cyclohexanediamine has a potential of anticancer activity.

  • Dacomitinib

    Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.

  • Lazertinib

    Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.